High Cost of Mpox Vaccine Discourages At-Risk Americans

Critics argue that the high cost of the Mpox vaccine is discouraging at-risk Americans from getting vaccinated, potentially undermining public health efforts to control the disease. The financial barrier may prevent vulnerable populations from accessing necessary protection, raising concerns about the accessibility and affordability of crucial healthcare services.